Researcher Óscar Millet presents the AKRIBEA project at the 15th RFMF Scientific Day in Perpignan

The 15th Scientific Day of the Réseau Francophone de Métabolomique et Fluxomique (RFMF) held in Perpignan, France, showcased groundbreaking research and advancements in the field of metabolomics and fluxomics. The event, which took place from May 24th to 26th, focused on the practical applications of metabolomics and fluxomics in various scientific domains, including precision medicine and its impact on biomedical practices.

Conventionally, disease diagnosis has been limited to the analysis of a few biomolecules, often relying on a simplistic association between specific metabolites and diseases. However, this approach provides an incomplete diagnostic picture. Precision medicine, on the other hand, considers patient-specific factors, such as genetics, environment, and lifestyle, along with molecular mechanisms to provide a more comprehensive approach to disease prevention and treatment.

In that context, lead researcher Óscar Millet from the “Precision Medicine and Metabolism Lab” at CIC bioGUNE, member of BRTA, presented the AKRIBEA project and its implications for precision medicine. During his conference entitled "Prospective Metabolomic Studies in Precision Medicine: the AKRIBEA Project", Óscar Millet emphasized on the limitations of conventional medicine in disease diagnosis and the potential of precision medicine to revolutionize healthcare.

Metabolomics, with its ability to capture the intricate interplay between genetic and environmental factors, emerges as a highly suitable technique for precision medicine. The AKRIBEA project, a part of the esteemed Precision Medicine Initiative of the Basque Country and The Complementary Plan for Biotechnology applied to Health, served as a compelling case study, demonstrating the integration of nuclear magnetic resonance (NMR) based metabolomics into precision medicine strategies.

The primary objective of the AKRIBEA project is to identify and validate predictive biomarkers for precise diagnosis and prognosis in the realm of precision medicine. By focusing on knowledge transfer associated with the concept of precision medicine, the project addresses the growing demand for personalized strategies in disease diagnosis, treatment, and prediction.

The identification of these molecules and pathways, coupled with excellent basic research, is essential for understanding their mechanisms of action and obtaining the knowledge necessary to modify existing therapies or design new ones, ultimately increasing therapeutic effectiveness against specific pathologies. Additionally, the integration of molecular knowledge and understanding of mechanisms of action will contribute to better patient diagnosis, classification, and more efficient therapeutic interventions, resulting in significant socio-economic impact.

About CIC bioGUNE

The Centre for Cooperative Research in Biosciences (CIC bioGUNE), member of the Basque Research & Technology Alliance (BRTA), located in the Bizkaia Technology Park, is a biomedical research organisation conducting cutting-edge research at the interface between structural, molecular and cell biology, with a particular focus on generating knowledge on the molecular bases of disease, for use in the development of new diagnostic methods and advanced therapies.

About BRTA

BRTA is an alliance of 4 collaborative research centres (CIC bioGUNE, CIC nanoGUNE, CIC biomaGUNE y CIC energiGUNE) and 12 technology centres (Azterlan, Azti, Ceit, Cidetec, Gaiker, Ideko, Ikerlan, Lortek, Neiker, Tecnalia, Tekniker and Vicomtech) with the main objective of developing advanced technological solutions for the Basque corporate fabric.

With the support of the Basque Government, the SPRI Group and the Provincial Councils of the three territories, the alliance seeks to promote collaboration between the research centres, strengthen the conditions to generate and transfer knowledge to companies, contributing to their competitiveness and outspreading the Basque scientific-technological capacity abroad.

BRTA has a workforce of 3,500 professionals, executes 22% of the Basque Country's R&D investment, registers an annual turnover of more than 300 million euros and generates 100 European and international patents per year.

Spanish version

See a large version of the first picture


El CIC bioGUNE participa en la jornada de innovación multidisciplinar en medicina personalizada

El Plan Complementario de Biotecnología aplicada a la Salud organiza la...



SEMINAR HIGHLIGHT: The Revolutionary Use of Artificial Intelligence in Protein Design and Engineering

The integration of AI in protein design and engineering has the potential...